Emergent BioSolutions develops, manufactures and sells protective and life-saving products for public health threats, including smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. It has two reportable segments.
- Commercial Products: NARCAN Nasal Spray, sold over the counter and through U.S. public interest and Canadian channels, plus KLOXXADO Nasal Spray, which is licensed from Hikma.
- MCM Products, sold mainly to the U.S. government and increasingly to international governments (13 countries supplied in Q3 2026):
- Anthrax: CYFENDUS, BioThrax, ANTHRASIL and raxibacumab.
- Smallpox: ACAM2000, CNJ-016 (VIGIV) and TEMBEXA.
- Botulism: BAT antitoxin.
A smaller Bioservices (contract manufacturing) operation and government contracts and grants revenue, notably Ebanga development work, are reported as all other revenues. MCM revenue is lumpy because it depends on the timing of USG annual purchase options and government funding.
The company is in a multi-year turnaround under CEO Joe Papa, focused on cost restructuring, debt reduction and international MCM expansion. It is also pursuing R&D programs, including a pan-Ebola mAb, TEMBEXA for mpox, a pandemic flu vaccine and U.S. distribution rights to IMOJEV. It is exploring partnerships with AI companies on biodefense. Updated
One of the key benefits of exchange traded funds (ETFs) is that they can offer immediate portfolio exposure to hundreds or even thousands of stocks. In that vein, two popular choices among…
Emergent BioSolutions develops, manufactures and sells protective and life-saving products for public health threats, including smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
What is the EBS stock price target?
The Wall Street consensus 12-month price target for EBS is $10.00.